While we all know that COVID-19 has promoted growth in the vaccine contract manufacturing market, what other factors are impacting the field? In this article, EPR’s Hannah Balfour summarises the trends and opportunities identified by a new market research report.
List view / Grid view
In an investor update, GlaxoSmithKline (GSK) revealed its plan to promote growth and performance over next ten years.
The UK’s competition authority will assess whether AstraZeneca’s acquisition of Alexion will result in a “substantial lessening of competition”.
The European Medicines Agency (EMA) has initiated a rolling reviews of Vero Cell, an inactivated COVID-19 vaccine, and sotrovimab, a monoclonal antibody.
In this article, Rich Quelch, Global head of marketing at Origin, discusses how the UK’s pharmaceutical supply chain could be adapted to increase its resilience to future disruptions and the challenges in doing so.
In this article, learn from GlaxoSmithKline’s and ViiV Healthcare’s team as they discuss the key elements that enabled them to build and set up a dedicated manufacturing facility for Rukobia in only 15 months.
Jemperli (dostarlimab) was granted accelerated approval after 42.3 percent recurrent or advanced endometrial cancer patients with deficient mismatch repair responded in a trial.
Under a new agreement, GlaxoSmithKline will provide the fill and finish manufacturing capacity for 60 million doses of Novavax’ COVID-19 vaccine for use in the UK.
The dose finding study will assess the safety, reactogenicity and immunogenicity of the companies’ investigational COVID-19 vaccine in 720 participants.
Research suggests that despite a COVID-19 slump, the anti-Parkinson’s drugs market will recover due to rising numbers of Parkinson’s diagnoses and increasing investment in R&D.
The ACTIV-3 sub-study will evaluate the safety and efficacy of the AZD7442 synthetic antibody combination in at least 150 participants with mild-to-moderate COVID-19.
A new report suggests artificial intelligence (AI) will be the most disruptive technology in the pharmaceutical industry this year and beyond.
When adjuvanted with GSK’s pandemic adjuvant system, the S-Trimer vaccine candidates induced the production of neutralising antibodies in all trial participants.
After purchasing an additional two million doses of Moderna's COVID-19 vaccine, the UK will now receive a total of 357 million doses of vaccines from seven developers.
GSK will use 100 percent renewable electricity usage among other efforts in its plans to have a net zero impact on the climate by 2030.